Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
(ABX - Get Report)
downgraded at BMO to Market Perform. Acquisition will double the company's exposure to base metals.
(CERN - Get Report)
rated new Underperform at Oppenheimer. $90 price target. Company is facing increased competition.
Community Health Systems
downgraded at Citi to Hold from Buy. Operations should be impacted by 2-3 year-long investigation overhang, Citigroup said. Price target lowered to $33 from $38.
(ECA - Get Report)
downgraded at Ticonderoga from Neutral to Sell, Ticonderoga Securities said. $27 price target. Company is being hurt by a weak natural gas market in North America.
rated new Perform at Oppenheimer. Claims processing business could eventually give way to direct claims submission.
upgraded at BofA/Merrill to Neutral. $9.50 price target. Company is outperforming its peers.
upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $61 price target. Company is leveraged to a late-cycle commerical construction recovery.
(JCI - Get Report)
price target boosted at Credit Suisse to $53 from $49. Strong 2Q11 results, amid Japan issues, Credit Suisse said. Maintain Outperform rating.
(JCI - Get Report)
upgraded at Deutsche from Neutral to Overweight, Deutsche Bank said. Company is seeing strong business momentum across the board. $47 price target.
rated new Outperform at Oppenheimer. $25 price target. Company is integrating its businesses ahead of plan.
(MGM - Get Report)
downgraded at Credit Suisse to Underperform from Neutral. Slow strip recovery worsened by high energy prices, Credit Suisse said. Price target cut to $11 from $14.
downgraded at Argus from Buy to Hold, Argus Research said. Volumes remain weak.
(NFLX - Get Report)
upgraded at Maxim from Sell to Hold, Maxim Group said. Company should continue to grow its subscriber base.
estimates increased at Goldman through 2013, Goldman Sachs said. Company is realizing higher operating margins. Buy rating and $300 price target.
downgraded at Janney to Sell. Valuation call, based on a $170 price target.